Blood Phoenixin-14 Levels and Echocardiographic Findings in Infants of Diabetic Mothers
Launched by KONYA CITY HOSPITAL · Mar 20, 2025
Trial Information
Current as of April 29, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how certain heart-related problems in newborns of mothers with diabetes might be linked to high levels of a substance called phoenixin-14 in their blood. The researchers want to understand if these elevated levels could help identify heart issues earlier in these infants. The study is currently recruiting participants, and it’s open to healthy term infants aged 1 to 5 who were born to mothers with diabetes.
To be eligible for the trial, infants must be healthy and born at full term (around 37 to 42 weeks of pregnancy). However, infants whose families do not give consent or who have heart defects or certain genetic conditions cannot participate. If your child is eligible and joins the study, they will likely undergo some tests, including heart scans, to help the researchers gather important information. This study aims to improve our understanding of how diabetes in mothers can affect their babies' heart health.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Infants of diabetic mothers
- • Healthy term infants
- Exclusion Criteria:
- • Infants whose families did not provide consent
- • Infants with a syndromic appearance or congenital heart disease
About Konya City Hospital
Konya City Hospital is a leading healthcare institution dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. With a commitment to excellence in patient care and a focus on collaborative research, the hospital integrates state-of-the-art facilities and a multidisciplinary team of experienced professionals. By participating in clinical trials, Konya City Hospital aims to contribute to the development of new therapies and enhance the understanding of various medical conditions, ultimately benefiting both the local community and the broader medical field.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Konya, Karatay, Turkey
Patients applied
Trial Officials
MELEK BUYUKEREN
Principal Investigator
Konya City Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported